肠道真菌与儿童炎症性肠病  

Gut mycobiome and pediatric inflammatory bowel disease

作　　者：刘清 汪志凌[1] Liu Qing;Wang Zhiling(Department of Pediatric Gastroenterology,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川大学华西第二医院小儿消化科、出生缺陷与相关妇儿疾病教育部重点实验室,成都610041

出　　处：《中华妇幼临床医学杂志（电子版）》2024年第2期172-178,共7页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：中华国际医学交流基金会资助项目(Z-2017-27-2001);四川省科技厅科技项目(2022YFS0026)。

摘　　要：肠道真菌是肠道微生态的重要组成部分,随着检测技术的进步,肠道真菌相关研究不断深入。肠道真菌与炎症性肠病(IBD)相关性,也逐渐引起儿童消化领域的重视,基于肠道真菌的干预措施,可能为IBD临床治疗提供一种新的策略。笔者拟就IBD患者的肠道真菌构成变化,以及其作为IBD诊治生物标志物与治疗手段可能性的最新研究现状进行阐述,旨在为临床认识肠道真菌与IBD的关系提供参考。Gut mycobiome(fungi)is a crucial component of the intestinal microecosystem homeostasis.The advancement of technology contributes greatly to new research in this field.More and more pediatric gastroenterology studies have focused on the relationship between intestinal fungi and IBD.Gut mycobiome-based interventions may provide a new strategy for the treatment of IBD.In this study,we intend to elaborate the latest research status of the composition changes gut mycobiome,its potential use as biomarkers and targets for the treatment of IBD,aiming to provide reference for clinical understanding of the relationship between intestinal fungi and IBD.

关 键 词：真菌 胃肠 炎性肠疾病 结肠炎 溃疡性 CROHN病 分子靶向治疗 念珠菌属 马拉色霉菌属 酵母菌 酿酒 儿童 

分 类 号：R725.7[医药卫生—儿科]